{ }
Novo Nordisk reported mixed Q3 2024 earnings, beating EPS expectations at $0.88 but slightly missing revenue at $10.2 billion. Wegovy sales surged 81% year-over-year to $2.5 billion, while the company tightened its 2024 outlook due to pricing and supply pressures, expecting sales growth of 23%-27%. Despite increased patient numbers, supply constraints for its GLP-1 drugs persist.
Novo Nordisk has confirmed that all doses of its GLP-1 medications, Ozempic and Wegovy, are now available in the U.S., ending a shortage that began in March 2022. Despite this, patients may still face challenges filling prescriptions due to variability at pharmacies. The company has invested significantly in manufacturing capacity to meet the high demand driven by the drugs' effectiveness in weight loss and reducing health risks.
Eli Lilly's third-quarter earnings fell short of Wall Street expectations, with revenue at $11.4 billion, missing forecasts of $12.1 billion. Sales of its obesity drugs, Mounjaro and Zepbound, reached $3.1 billion and $1.26 billion, respectively, but were lower than anticipated, leading to a significant drop in shares and a revised revenue guidance for the year. Despite these setbacks, company executives noted continued growth in underlying demand for their products.
Big Pharma has increased its lobbying efforts in the 2024 election, with significant contributions flowing to both Democrats and Republicans. Notably, Harris has received nearly $1.7 million from the pharma sector, while Trump garnered just over $300,000. Companies like Eli Lilly and Amgen are actively engaging in political donations, with Amgen favoring Republicans, while Roche and AstraZeneca show a slight Republican lean but with declining contributions.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.